The use of genetic information in large-scale clinical trials: Applications to Alzheimer research

Alzheimer Disease and Associated Disorders

Volumn 10, Issue SUPPL. 1, 1996, Pages 22-26

  Schork, Nicholas J ^a,b,c,d,f   Weder, Alan B ^e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d JACKSON LABORATORY   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Genetic information; Responsiveness to drugs

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DEBRISOQUINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ALZHEIMER DISEASE; ANTHROPOMETRY; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFICACY; DRUG SCREENING; GENE LOCUS; HUMAN; HYPERTENSION; LABORATORY TEST; MEDICAL GENETICS; MEDICAL INFORMATION; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0029811380     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199601031-00007     Document Type: Review

References (24)

1. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet 1994;7:180-3.
2. Gerbase-DeLima M, Ladalardo MA, DeLima JJ, Silva HB, Bellotti G, Pileggi F. Essential hypertension and histocompatibility antigens: an association study. Hypertension 1992;19:400-2.
3. Heise ER, Moore MA, Reid QB, Goodman HO. Possible association of MN locus haplotypes with essential hypertension. Hypertension 1987;9:634-40.
4. Jeunemaitre X, Lifton RP, Dluhy RB, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992a;71:169-80.
5. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR, Lalouel JM. Absence of linkage between the angiotensin-converting enzyme locus and human essential hypertension. Nature Genet 1992b;1:72-5.
6. La Du BN. Overview of pharmacogenetics. In: Kalow W, ed. Pharmacogenetics and drug metabolism. New York: Pergamon Press, 1992:1-12.
7. Lifton RP, Dluhy RB, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992;355:262-5.
8. Pericak-Vance MA, Haines JL. Genetic epidemiology to Alzheimer disease. Trends Genet 1995;11:504-10.
9. St. George-Hyslop PH, Tanzi R, Polinsky R, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987;235:885-9.
10. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992;258:668-71.
11. +-adenosine triphosphatase alleles and essential hypertension. J Hypertens 1992;10:1005-10.
12. Schunkert H, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994;330:1634-8.
13. Schuster LA. Pharmacogenetic approach to the brain. In: Leiblich L, ed. Genetics of the brain. New York: Elsevier Biomedical Press, 1982:423-36.
14. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450 db1 gene (P450 C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988;85:5240-3.
15. Smith CK. Spectra biomedical sees future in personalized genetic profiling services. Genet Engin News 1996;17:10,28.
16. Summers WK, Majovski LV, Marsh GM, Tchiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-5.
17. Sun L, Schulte N, Pettinger P, Regan JW, Pettinger WA. The frequency of alpha-2-adrenoreceptor restriction fragment length polymorphisms in normotensive and hypertensive humans. J Hypertens 1992;10:1011-5.
18. Szpirer C, Riviere M, Szpirer J, et al. Chromosomal assignment of human and rat hypertension candidate genes: type I angiotensin II receptor genes and the SA gene. J Hypertens 1993;11:919-25.
19. Weder AB, Julius S. Pathophysiology of hypertension and treatment. In: Singh BJ, Dzau VJ, VanHoote PM, Woosley RC, eds. Cardiovascular pharmacology and therapeutics. New York: Churchill-Livingstone, 1994:861-83.
20. Weinberger MH. Association of haptoglobin with sodium sensitivity and resistance of blood pressure. Hypertension 1987;10:443-6.
21. Wilcock GK, Scott MI. Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet 1994;344:544.
22. Wilson AF, Elston RC, Tran LD, Siervogel RM. Use of the robust sibpair method to screen for single-locus, multiple-locus, and pleiotropic effects: application to traits related to hypertension. Am J Hum Genet 1991;48:862-72.
23. Zee RYL, Ying LH, Morrsie BJ, Griffiths LR. Association and linkage analyses of restriction fragment length polymorphisms for the human renin and antithrombin III genes in essential hypertension. J Hypertens 1991;9:825-30.
24. Zee RYL, Lou Y, Griffiths LR, et al. Molecular genetic analysis of RFLPs for PCR-amplified growth hormone gene, renal kallikrein gene and atrial natriuretic factor gene in essential hypertension. Hypertens Res 1993;16:113-20.